Description

Plerixafor is a selective antagonist of the CXCR4 chemokine receptor, playing a critical role in hematopoietic stem cell mobilization. Its primary commercial value lies in its use as an active pharmaceutical ingredient (API) for the production of life-saving oncology and hematology therapeutics. This compound is essential for manufacturers in the global pharmaceutical industry, particularly those developing and producing treatments for non-Hodgkin's lymphoma and multiple myeloma. Plerixafor CAS NO 1246819-87-3 represents a high-purity, synthetically complex molecule where supply chain reliability and stringent quality control are paramount.

Application

• Pharmaceutical API: Primary use as the active ingredient in stem cell mobilizing drugs (e.g., Mozobil®/Plerixafor injection) for autologous transplantation in patients with lymphoma and multiple myeloma.
• Oncology Research: A key tool compound in preclinical research for studying the CXCR4/CXCL12 axis, which is implicated in cancer metastasis, angiogenesis, and tumor microenvironment interactions.
• Hematopoietic Stem Cell (HSC) Mobilization: Used in clinical settings to mobilize HSCs from the bone marrow to the peripheral blood for collection prior to autologous transplantation.
• Immunology & Inflammation Studies: Investigated for potential applications in modulating immune cell trafficking in various inflammatory and autoimmune conditions.
• HIV Research: Historically studied for its potential to block HIV entry into cells via CXCR4 co-receptor antagonism, contributing to virology research tools.
• Formulation Development: Serves as a reference standard and raw material for the development of generic and novel drug formulations, including injectables.

Basic Information

Product Name	Plerixafor
CAS No.	1246819-87-3
Molecular Formula	C28H54N8
Molecular Weight	502.78 g/mol
Synonyms	AMD 3100; JM 3100; Mozobil; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane; Plerixafor octahydrochloride (salt form precursor); Cyclam, 1,1'-[1,4-phenylenebis(methylene)]bis-; CXCR4 antagonist AMD3100
EINECS	Contact for details

Quality Control

Our Plerixafor is manufactured under strict quality management systems to ensure it meets the exacting standards required for pharmaceutical applications. Each batch is subjected to comprehensive analytical testing, including identity confirmation, purity assay, and impurity profiling via advanced techniques like HPLC and mass spectrometry. We provide full traceability and support regulatory filings with detailed documentation. Certificates of Analysis (COA) are available upon request, confirming compliance with relevant pharmacopeial monographs (e.g., USP) and customer-specific specifications.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive) and must be kept under inert conditions (e.g., nitrogen atmosphere) in the original packaging to prevent degradation. For long-term storage, consider storing at 2-8°C.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference standard
Identification (HPLC)	Retention time matches reference
Assay (HPLC)	≥98.0% (on anhydrous basis)
Water Content (KF)	≤1.0%
Residue on Ignition	≤0.1%
Heavy Metals	≤20 ppm
Related Substances (HPLC)	Total impurities ≤2.0% Any single impurity ≤0.5%
Microbial Enumeration	Meets Ph. Eur. 2.6.12/2.6.13

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.